A*STAR Infectious Diseases Labs (A*STAR IDL)

Researchers uncovered how specialised stem cells act as building blocks for the esophagus, shaping its development and offering insights into treating related diseases.

A*STAR researchers find that ordinary communications between immune cells during chikungunya virus infection can drive joint inflammation seen in the disease.

Through its focus on attracting, developing and retaining talents in science and technology, A*STAR is helping to build a rich national ecosystem of research, innovation and enterprise.

Antibodies in mucous membranes may be key in protecting against SARS-CoV-2 variants, pointing to the need for COVID-19 vaccines that target these antibody responses.

Research suggests monitoring individuals previously infected with Zika virus for chronic skin diseases caused by overactive T cells.

While the new Omicron XBB COVID-19 subvariant deftly dodges immune defences even in vaccinated individuals, researchers find that mixed mRNA vaccines may offer a vital boost of protection.

A study reveals how age, SARS-CoV-2 variants and booster shots affect immune responses to the COVID-19 vaccine.

Scientists survey how the mpox virus spreads through populations, the immunology of infections and current treatment interventions.

A novel tissue-profiling approach provides new insights into the mechanisms of fatal COVID-19 by analysing
different molecules and cell populations within organs.

Inactivated COVID-19 vaccines could be an equally potent alternative for people with allergic sensitivities to mRNA-based vaccines.

An analysis of cellular immune responses reveals that mixing COVID-19 vaccines and boosters may offer enhanced protection for at-risk populations.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.